Last reviewed · How we verify
TSHA-101
At a glance
| Generic name | TSHA-101 |
|---|---|
| Sponsor | Dr. Anupam Sehgal |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TSHA-101 CI brief — competitive landscape report
- TSHA-101 updates RSS · CI watch RSS
- Dr. Anupam Sehgal portfolio CI